Dong Guo1,2, Jinbao Zhang1, Wang Jing2,3, Jiafeng Liu4, Hui Zhu2, Lei Fu2, Minghuan Li2, Li Kong2, Jinbo Yue2, Jinming Yu2. 1. Weifang Medical University, Weifang, PR China. 2. Department of Radiotherapy, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, PR China. 3. Department of Radiotherapy, The First Affiliated Hospital to Zhengzhou University , Zhengzhou, PR China. 4. Department of Radiotherapy, Rizhao Center Hospital, Rizhao, PR China.
Abstract
AIM: We aimed to investigate the association between systemic immune-inflammation index (SII) and the clinical outcomes in patients with advanced non-small-cell lung cancer. MATERIALS & METHODS: The SII was calculated as platelet (P) × neutrophil (N)/lymphocyte (L), and the data were obtained within 1 week before treatment. Kaplan-Meier analysis and Cox proportional hazard models were used to assess the prognostic value of SII. RESULTS: Kaplan-Meier analyses revealed that the higher SII group was associated with poorer progression-free survival (p < 0.001) and poorer overall survival (p < 0.001). Multivariable Cox analysis further revealed SII as an independent prognostic factor for overall survival (p = 0.010) and progression-free survival (p = 0.001). CONCLUSION: SII can serve as a useful biomarker to predict recurrence and death for patients with advanced non-small-cell lung cancer.
AIM: We aimed to investigate the association between systemic immune-inflammation index (SII) and the clinical outcomes in patients with advanced non-small-cell lung cancer. MATERIALS & METHODS: The SII was calculated as platelet (P) × neutrophil (N)/lymphocyte (L), and the data were obtained within 1 week before treatment. Kaplan-Meier analysis and Cox proportional hazard models were used to assess the prognostic value of SII. RESULTS: Kaplan-Meier analyses revealed that the higher SII group was associated with poorer progression-free survival (p < 0.001) and poorer overall survival (p < 0.001). Multivariable Cox analysis further revealed SII as an independent prognostic factor for overall survival (p = 0.010) and progression-free survival (p = 0.001). CONCLUSION: SII can serve as a useful biomarker to predict recurrence and death for patients with advanced non-small-cell lung cancer.
Entities:
Keywords:
advanced; non-small-cell lung cancer; prognostic; systemic immune-inflammation index
Authors: Jingjing Kang; Matthew S Ning; Han Feng; Hongqi Li; Houda Bahig; Eric D Brooks; James W Welsh; Rui Ye; Hongyu Miao; Joe Y Chang Journal: Int J Radiat Oncol Biol Phys Date: 2019-10-03 Impact factor: 7.038
Authors: Emily Keit; Brendan Coutu; Weining Zhen; Chi Zhang; Chi Lin; Nathan Bennion; Apar Kishor Ganti; Vinicius Ernani; Michael Baine Journal: Ann Transl Med Date: 2021-02
Authors: Tithi Biswas; Kylie H Kang; Rohin Gawdi; David Bajor; Mitchell Machtay; Charu Jindal; Jimmy T Efird Journal: Int J Environ Res Public Health Date: 2020-10-30 Impact factor: 3.390